None listed
Conditions
Interventions
Intervention1: Caraflame: Caraflame-PQNS capsule 505.4mg once daily after lunch for 14 days
Control Intervention1: Placebo: Placebo
Sponsors
Crassula Healthcare Solutions Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Healthy Human participants of 18- 35 years weighing about 60-70kgs. 2.A body mass index within 18.50- 27.00 Kg/m2 (both inclusive). 3.Given informed consent to participate in the trial 4.Must have baseline serum CK, IL-6 and Myoglobin levels within normal laboratory reference ranges. 5.Must not undergone lower-body strength training in last 03 months. 6.Be Recreationally active but not resistance trained. 7.Must be non-smoker (at least 1 year prior to trial) 8.Participants/LAR must be capable of giving informed consent, and written consent must have been obtained prior to any study procedures. 9.Must be Willing to comply with 14-day pre-loading, Study procedure, visit schedules and protocol requirements in the opinion of investigator.
Exclusion criteria
Exclusion criteria: 1.Hypersensitivity reaction to the study medication 2. Abnormal Creatine Kinase baseline values above upper limit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome: Change in levels of Biomarkers of inflammation from Baseline and after exercise on Day 14 Timepoint: Change in levels of Biomarkers of Inflammation post exercise on Day 14 (1.00, 2.00, 3.00, 24.00 and 48.00 Hours) from Base line | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To assess the DOMS (Delayed Onset Muscle Soreness Scale) 2. To monitor the safety of the participants Timepoint: changes in DOMS post exercise on Day 14 from baseline Safety assessment on Day 14 from Baseline | — |
Countries
India
Contacts
Public ContactDr Bhawana Gupta
Crassula Healthcare Solutions Pvt Ltd
Outcome results
None listed